McKesson Ventures was among the existing investors that provided $25m through a private placement that supported the deal between Augmedix and Malo Holdings.

Kidney disease-focused drug developer Walden was co-founded by faculty members of Rush University and Harvard University earlier this year.

Baidu-backed surgical telemedicine system developer Avail Medsystems notched up a series B round that hiked its overall funding to $125m.

The Novo-backed CAH therapy developer has set the range for an offering set to net it between $60m and $80m in proceeds.

UCB Pharma co-led a series A round for the kidney disease-focused drug developer through its UCB Ventures vehicle.

Medical transcription technology provider Abridge has emerged from stealth with seed and series A funding.

Blood test provider Lumos Diagnostics secured $17.9m and aims to go public in a 2021 IPO that would provide an exit for series A lead investor Planet Innovation.

MIT's cancer therapy developer has set terms for an offering that will raise more than $185m if it floats at the top of its range.

10x Genomics has bought Harvard's genetic sequencing system provider and also revealed it closed its purchase of Stockholm University spinout CartaNA.

The GV-backed health insurance provider has agreed to merge with a special purpose acquisition company in a deal that will value it at $3.7bn.